MedTrace Logo

Gene Expression Profile of Resected Pancreatic and Ampullary Adenocarcinoma at Favorable Prognosis

NCT05754788 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2023-05-26

No results posted yet for this study

Summary

The study aims at evaluating spatially resolved gene expression profiles of pancreatic and ampullary adenocarcinoma at favorable prognosis after surgical resection, in order to identify molecular features associated to a less aggressive biologic behavior that may benefit from upfront surgery.

Conditions

  • Resectable Pancreatic Adenocarcinoma

Sponsors & Collaborators

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-19
Primary Completion
2023-05-31
Completion
2023-09-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05754788 on ClinicalTrials.gov